Practical Application of Immuno-Oncology in Renal Cell Carcinoma

Listen to Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for first-line immunotherapy treatment of advanced renal cell carcinoma.

Elizabeth R. Plimack, MD, MS
Program Director Brian A. Costello, MD, MS Martin H. Voss, MD Released: August 31, 2020

Listen to Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for treatment options in second-line and beyond for your patients with advanced renal cell carcinoma.

Brian A. Costello, MD, MS Elizabeth R. Plimack, MD, MS Martin H. Voss, MD Released: September 8, 2020

Listen to Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss clinical management pearls for IO-based therapy in patients with renal cell carcinoma.

Brian A. Costello, MD, MS Elizabeth R. Plimack, MD, MS Martin H. Voss, MD Released: September 21, 2020

How do you select first-line therapy for your patients with advanced RCC? In this commentary, Drs. Brian A. Costello and Martin H. Voss discuss the latest clinical data on immuno-oncology combinations for frontline therapy in advanced RCC.

Brian A. Costello, MD, MS Martin H. Voss, MD Released: August 18, 2020

Download this slideset from M. Dror Michaelson, MD, PhD, on his perspective for the optimal use of systemic therapy in the first-line setting for favorable-risk patients with advanced RCC.

Brian A. Costello, MD, MS M. Dror Michaelson, MD, PhD Released: February 13, 2020

Download this slideset from Martin H. Voss, MD, to learn more about selecting optimal first-line therapy for intermediate-risk/poor-risk patients with advanced RCC.

Martin H. Voss, MD Released: February 13, 2020

Download this slideset from Elizabeth R. Plimack, MD, MS, to see the latest data on treatment options for advanced RCC after previous therapy as well as how to manage AEs associated with RCC therapy.

Elizabeth R. Plimack, MD, MS
Program Director Released: February 13, 2020

Use this mobile-friendly interactive algorithm tool to receive National Comprehensive Cancer Network^® (NCCN^®) guidance on optimal management of immune-related adverse events associated with immune checkpoint inhibitor therapy, adapted from the NCCN Guidelines for Management of Immunotherapy-Related Toxicities v1.2020.